RxDoctor Payments Data

Poonam Singh, MD

Internal Medicine · Rome, GANPI 1457346496

Payments from drug & device makers

$443in general payments, 2019–2025

Across 22 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$153
  • Novo Nordisk$40
  • Valeritas, Inc.$33
  • GSK$28
  • AstraZeneca$27
  • Astellas Pharma US Inc$21
  • plus $140 from 8 others

What the payments were for

  • Food & beverage$443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$443 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$199,096
Medicare patients
508
Services billed
8,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide249$291,956
OzempicSemaglutide154$192,530
EliquisApixaban130$111,651
TradjentaLinagliptin131$102,538
RemicadeInfliximab11$74,926
ProliaDenosumab41$69,726
GlyxambiEmpagliflozin/Linagliptin50$58,738
JardianceEmpagliflozin45$54,756
Tresiba Flextouch U-200Insulin Degludec18$45,018
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$41,579
JanuviaSitagliptin Phosphate28$38,891
Janumet XrSitagliptin Phos/Metformin Hcl35$30,923
Breo ElliptaFluticasone/Vilanterol28$25,397
LinzessLinaclotide28$25,292
SymbicortBudesonide/Formoterol Fumarate57$22,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$17$315,788272 claims
Novo NordiskOzempic, Rybelsus$40$213,670166 claims
PfizerEliquis$16$111,651130 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$28$75,82693 claims
Johnson & JohnsonRemicade$15$74,92611 claims
AmgenProlia$17$69,72641 claims
AstraZenecaSymbicort, Farxiga$27$39,99775 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →